MarketPulse

CRISPR

3 articles
Investing.comInvesting.com··Chris Markoch

Gene-Editing Pioneers Emerge as M&A Targets Amid $300B Biotech Patent Cliff

Biotech M&A surges as $300B patent cliff looms by 2030. Three gene-editing firms positioned as acquisition targets offer varying risk profiles.
BMYCELGrMRKBEAMCRSP+1patent cliffCRISPR
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Editas Medicine Slashes Q4 Losses While Advancing CRISPR Therapy Toward Human Trials

Editas Medicine reported Q4 2025 net loss of $5.6M, down 88% YoY. Lead CRISPR therapy EDIT-401 shows >90% LDL-C reduction; IND submission expected mid-2026.
BMYCELGrEDITclinical trialCRISPR
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Vertex Pharmaceuticals Outpaces Centessa With Established Revenue and Advanced Pipeline

Vertex Pharmaceuticals outperforms Centessa with profitable cystic fibrosis revenue, successful product launches, and advanced pipeline, offering lower-risk investment profile versus pre-revenue competitor.
VRTXCNTAbiotechclinical trials